US/UK/Canada

Share

Contacts

  • Scandinavian ChemoTech AB
    Medicon Village Scheelevägen 2 223 63 Lund
    010-2189300
    http://www.chemotech.se
  • Mohan Frick

    CEO


    0707752411
    • Pick a time period -
    Tags ( Active)

    Scandinavian ChemoTech Splits Business Units to Boost Cash Flow and will suggest a new name for the group

    Since 2021, Scandinavian ChemoTech has operated two distinct business units - Human Care and Animal Care. While Human Care was the group’s initial focus, the Board of Directors has made key decisions to support the independence and growth of the two separate entities. By separating the successful cash generating Animal Care unit from the more complex processes of Human Care, where much of the company’s burn rate is concentrated, resources can be reallocated to boost sales activities within Animal Care. With these changes the company anticipates annual savings of 2-3 MSEK, which can be

    Scandinavian ChemoTech’s Animal Care is heading towards a strong fourth quarter 2024 in terms of sales

    Animal Care is on track to close 2024 on a high note, with sales in the fourth quarter already reaching approximately 1,500 KSEK and projected to surpass 6,000 KSEK for the full year. This highlights the increasing adoption and success of our vetIQure™ TSE system and treatment kits in the veterinary market.   A key driver of this growth is the rising number of repeat purchases from existing customers. This demonstrates not only the trust our customers place in the vetIQure™ TSE system but also its growing utilization in veterinary practices—an encouraging sign of its effectiveness and

    Scandinavian ChemoTech AB (publ) Executive Summary of Interim report Q3 January – September 2024

    Third quarter · Net sales amounted to kSEK 1 499 (1 080) · Profit before tax amounted to kSEK -3 243 (-4 526) · Earnings per share amounted to SEK -0,14 (-0,33) · Cash flow from operating activities totaled to kSEK -5 567 (-4 649) Period 1 January - 30 September · Net sales amounted to kSEK 4 525 (2 315) · Profit before tax amounted to kSEK -10 550 (-15 943) · Earnings per share amounted to SEK -0,53 (-1,22) · Cash flow from operating activities totaled to kSEK -10 973 (-14 831)  Important events during the quarter · Last day for trading with BTA was

    ChemoTech’s Animal Care Enters Strategic Collaboration with Norwegian Veterinary University’s Hospital for Equine Medicine

    Scandinavian ChemoTech AB’s subsidiary dedicated to Animal Care has entered a clinical partnership with the Norwegian University of Life Sciences (NMBU) Hospital for Equine Medicine. Following an extensive evaluation period, NMBU’s Equine team, led by Professor and DVM Cathrine Fjordbakk, has decided to integrate ChemoTech’s Tumour-Specific Electroporation (TSE) therapy into their routine treatment offerings. This partnership aims to set new standards in veterinary oncology and reach new scientific milestones.   This collaboration and commercial agreement not only strengthen the

    Animal Care Secures New Sale in Germany, Expanding Support for Veterinary Clinics Treating Domestic Animals

    Scandinavian ChemoTech’s Animal Care is pleased to announce a recent sale of its vetIQure™ TSE device with treatment kits to veterinary practice Christoph Sonntag in Germany specializing in the care of domestic animals, with a focus on dogs and cats. This latest partnership further establishes our commitment to providing high-quality solutions to animal healthcare providers in Europe.   “We’re excited to support the evolving needs of veterinary clinics in Germany that are dedicated to the health and well-being of pets,” said Mohan Frick, CEO. “This sale is a testament to the trust

    Scandinavian ChemoTech’s Chief Medical Officer, Suhail Mufti, delivers clinical update

    This is the second clinical update following the introduction of TSE (Tumour Specific Electroporation™) in the curative treatment line of Head and Neck (H&N) cancer at AIIMS Jodhpur. In this update, CMO Suhail Mufti provides insights into the long-term clinical study objectives and key milestones.     Clinical Trial Progress in University Hospital in Jodhpur India, non-sponsored trials:   1. Patient enrolment began as scheduled, following the Ethics Committee approval of the revised clinical study protocol, as publicly announced on November 29, 2023. 2. The latest protocol

    Scandinavian ChemoTech’s Animal Care Announces New Partnership

    Scandinavian ChemoTech’s is proud to announce a new order secured with a Specialty Animal Care Clinic in Colorado, USA. This new collaboration, valued at approximately USD 40,000, marks another step towards developing the USA market for vetIQure™ and a further achievement in our commitment to advancing veterinary care around the world.   Colorado is the 21st largest state in terms of population in the U.S. and ranks 8th in terms of median household income, at USD 82,254. Within the state, approximately 47.2% of households own a pet, which includes a mix of dogs, cats, and other small

    Correction of press release published on 3 September 2024 regarding first commercial order on a TSE SYSTEM

    Scandinavian ChemoTech published a press release on 3 September 2024 regarding a first commercial order on a TSE SYSTEM. In the press release, the counterparty’s name was mentioned which was not allowed under the agreement with the counterparty. Below is a correct press release without the counterparty’s name and a clarification that the order of the TSE system includes consumables.   Animal Care Receives its First Commercial Order for a TSE System from a Large Animal Clinic in Sweden   Scandinavian ChemoTech’s subsidiary Vetiqure AB, proudly announces an order, for a complete

    Animal Care Receives its First Commercial Order for a TSE System from a Large Animal Clinic in Sweden

    Scandinavian ChemoTech’s subsidiary Vetiqure AB, proudly announces an order, for a complete TSE system including consumables, worth approximately EUR 40,000 from a prominent a leading clinic in oncological animal care in Sweden, which is a part of one of the largest veterinary medicine organisations.   This significant order is a result of an extensive evaluation period where the hospital evaluated vetIQure™ and the TSE treatment.   "We are happy to be able to continue to build on our relationship and hope that this collaboration will expand to other hospitals and clinics in

    Scandinavian ChemoTech AB (publ) Executive summary of Interim report Q2 January – June 2024

    Second quarter · Net sales amounted to kSEK 1 681 (1 181) · Profit before tax amounted to kSEK -4 104 (-6 383) · Earnings per share amounted to SEK -0,23 (-0,48) · Cash flow from operating activities totaled to kSEK -553 (-5 477) Period 1 January - 30 June · Net sales amounted to kSEK 3 026 (1 235) · Profit before tax amounted to kSEK -7 307 (-11 417) · Earnings per share amounted to SEK -0,41 (-0,90) · Cash flow from operating activities totaled to kSEK -5 406 (-10 182) Important events during the quarter · ChemoTech obtained patent protection for two

    Scandinavian ChemoTech’s Animal Care Announces New Partnership

    Scandinavian ChemoTech’s Animal Care proudly begins the third quarter of 2024 by securing a significant new order with The Woodlands Animal Cancer and Referral Center in Houston, Texas, one of the ten most populated cities in the USA. This order amounts to approximately USD 36,000 and marks another milestone in our commitment to advancing veterinary care.   The Woodlands Animal Cancer and Referral Center, one of the leading veterinary specialty hospitals in the Greater Houston area, has added our innovative vetIQure™ TSE system its state-of-the-art facility. This addition is a

    Scandinavian ChemoTech’s Chief Medical Officer, Suhail Mufti, provides an update on the clinical development and strategy of Medical Affairs

    After the entry of TSE (Tumour Specific Electroporation™) in the curative lines of therapy for Head and Neck (H&N) cancer at AIIMS Jodhpur, ChemoTech brings updates on its long-term clinical targets and ongoing projects.   Clinical strategy Apart from continued validation of the beneficial effects in superficial tumours and palliative care settings, the clinical development goals of TSE are focused on earlier and curative lines of cancer treatment in combination with other therapies, especially immunotherapy, including deep-seated tumours.   Clinical Trial Progress  1.

    Animal Care Experiences Significant Surge in Customer Adoption, Bolstering Confidence in Product Efficacy and Health Economic Metrics

    Scandinavian ChemoTech’s Animal Care operation is excited to announce a significant increase in the adoption of its vetIQure™ TSE system.  This trend underscores the system’s effectiveness and its critical value to everyday oncology practices. Some clinics are now performing more than five TSE treatments per day, potentially exceeding 200 treatments annually. This is a significant increase from our earlier estimate of approximately 100 treatments per year.   In recent quarters, the Company has observed a marked rise in repeat purchases, reflecting the growing trust and satisfaction

    (RETRANS) Animal Care goes towards a new sales record as another order is secured

    Retransmission of the press release that was published, with the associated MAR label, on June 4th, 2024, at 19:00 CET.   Scandinavian ChemoTech's Animal Care operation continues to thrive, securing a new order just days after achieving a record-breaking month. This latest order, from United Veterinary Care (UVC) in Springfield of USD 46,000, brings our collective sales for the second quarter to EUR 134,000 so far, surpassing the previous record quarter (EUR 124,400).   Each month, with every installation of the vetIQure™ TSE system, we move closer to a cashflow-positive

    Animal Care goes towards a new sales record as another order is secured

    Scandinavian ChemoTech's Animal Care operation continues to thrive, securing a new order just days after achieving a record-breaking month. This latest order, from United Veterinary Care (UVC) in Springfield of USD 46,000, brings our collective sales for the second quarter to EUR 134,000 so far, surpassing the previous record quarter (EUR 124,400).   Each month, with every installation of the vetIQure™ TSE system, we move closer to a cashflow-positive operation. United Veterinary Care is a leading, fast-growing veterinary chain in the United States, known for its primary, specialty,

    Animal Care Achieves Record Sales in May 2024 for its vetIQure™ TSE system

    Scandinavian ChemoTech is proud to announce that its Animal Care operations has achieved another record month of sales in May 2024. This exceptional performance underscores the growth and the increasing market demand for its innovative veterinary solution; the vetIQure™ TSE (Tumour Specific Electroporation™) system. The remarkable sales figures for May are attributed to the growing popularity and successful adoption of ChemoTech's vetIQure TSE system across key markets in North America and Europe, including previously announced significant new orders totalling more than EUR 92,000 from

    ChemoTech's Animal Care Division Secures important order in Germany for a vetIQure™ TSE system

    Scandinavian ChemoTech AB is pleased to announce that its Animal Care division has secured a significant order for a new vetIQure™ TSE system from TeamVet Group in Germany. The order is worth 48,000 EUR and in total, sales have reached 85,000 EUR in May so far.   Equine clinic Burg Müggenhausen is one of the most renowned and innovative referral equine hospitals in Germany and part of TeamVet group. TeamVet is an independent network of selected veterinary clinics and practices in Germany, focusing on the sustainable development of their facilities. Their philosophy emphasizes autonomy

    ChemoTech's Animal Care Initiates Launch of TSE Cancer Treatment Technology in Canada with first order

    Scandinavian ChemoTech’s Animal Care has received an initial order valued to USD 37,000 from a veterinary clinic in Ottawa, Canada. This order is contingent upon a successful electrical safety test conducted by a third-party testing facility. Since the vetIQure™ device is based on the same platform as the CE-marked IQwave™, the testing process is expected to be successful and take approximately 3-6 weeks.   Capital City Specialty & Emergency Animal Hospital is part-owned by Dr. Julius M. Liptak, a highly respected figure in veterinary surgical oncology. Dr. Liptak's passion and

    Scandinavian ChemoTech AB (publ) Executive Summary of Interim report Q1 January – March 2024

    First quarter · Net sales amounted to kSEK 1 345 (54) · Profit before tax amounted to kSEK -3 203 (-5 034) · Earnings per share amounted to SEK -0,18 (-0,42) · Cash flow from operating activities totaled to kSEK -4 853 (-4 705) Important events during the quarter · The Ethics Committee of the University Hospital of Jodhpur approves the change in the study protocol for the treatment of head and neck cancer and places TSE within the curative treatment options. · ChemoTech is aligning its strategy and short-term goals for Human Care. · ChemoTech’s Animal Care

    Scandinavian ChemoTech announces departure of QM & RA Director Eva Ståhl Wernersson

    After three years as QA/RA manager in Scandinavian ChemoTech's management team, Eva Ståhl Wernersson now chooses to leave her consulting role in the Company and move on to new challenges.   Eva Ståhl Wernersson has played a crucial role at ChemoTech, demonstrating considerable dedication to ensuring the company's compliance with regulations and quality assurance standards. One of her notable achievements includes leading the effort to obtain CE marking for the IQwave 3.0 CE system, our flagship product.   "I am grateful for the opportunity to have led our regulatory and quality

    ChemoTech obtain approval of the third and last patent application in India

    Scandinavian ChemoTech AB today announces that it has been granted its third and last patent application by The Patent Office, Government of India. The approved patent application pertains to the utilization of TSE for pain alleviation.   The Patent Office, Government of India has approved the third and final patent application. This approval allows for the utilization of TSE by delivering dynamic electrical pulses with pinpoint accuracy to specific body parts of mammals, enabling effective pain management, in amongst others deep seated tumours. The protection extends to 2038.

    ChemoTech attains progress by obtaining patent protection for two essential patents in India

    Scandinavian ChemoTech AB today announces that it has been granted two significant patent approvals by The Patent Office, Government of India. This implies that there won't be a requirement to engage in public tenders; rather, a simplified procurement process will be in place.   The Patent Office, Government of India has approved two of the Company's patent applications. The now granted patent is a protection of the proprietary TSE technology, specifically, the creation of dynamic pulses, as well as the specialised probe and treatment kits, the protection extends to 2038.   It

    Scandinavian ChemoTech’s Animal Care embarks on an exciting journey along with Equitom to forge a cutting-edge Centre of Excellence

    Vetiqure are expanding their partnership with Equitom, Europe's foremost equine clinic renowned for its groundbreaking advancements in equine healthcare, by establishing a Centre of Excellence for TSE.   With its distinguished reputation and status as the largest and most innovative equine clinic in Europe, Equitom has consistently pushed the boundaries of equine medicine. Vetiqure's TSE technology has been recognized by Equitom as a game-changer in the treatment of, amongst others, sarcoids, a common tumour among horses.   Following the successful integration of the vetIQure™

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media